17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details
臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05634876 (ClinicalTrials.gov) | April 2023 | 23/11/2022 | UB-312 in Patients With Synucleinopathies | A Phase 1b Clinical Trial of UB-312 in Patients With Synucleinopathies | Multiple System Atrophy;Parkinson Disease | Biological: UB-312 Injection;Biological: Placebo Injection | NYU Langone Health | NULL | Not yet recruiting | 40 Years | 75 Years | All | 8 | Phase 1/Phase 2 | United States |
| 2 | NCT04680065 (ClinicalTrials.gov) | April 2023 | 15/12/2020 | GDNF Gene Therapy for Multiple System Atrophy | Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy | Multiple System Atrophy | Biological: AAV2-GDNF gene therapy;Procedure: Sham (Placebo) Surgery | Brain Neurotherapy Bio, Inc. | NULL | Recruiting | 35 Years | 75 Years | All | 9 | Phase 1 | United States |
| 3 | NCT05732415 (ClinicalTrials.gov) | March 1, 2023 | 8/2/2023 | Biomarker Study of ATH434 in Participants With MSA | An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy | Multiple System Atrophy | Drug: ATH434 | Alterity Therapeutics | NULL | Not yet recruiting | 30 Years | 75 Years | All | 15 | Phase 2 | United States |
| 4 | NCT05696717 (ClinicalTrials.gov) | March 2023 | 13/1/2023 | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension;MSA - Multiple System Atrophy | Drug: Ampreloxetine;Drug: Placebo | Theravance Biopharma | NULL | Not yet recruiting | 30 Years | N/A | All | 102 | Phase 3 | NULL |
| 5 | NCT05695378 (ClinicalTrials.gov) | February 27, 2023 | 22/12/2022 | Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy | Multiple System Atrophy | Drug: KM-819;Drug: Placebo | Kainos Medicine Inc. | Parexel | Recruiting | 30 Years | 80 Years | All | 78 | Phase 2 | Korea, Republic of |
| 6 | NCT05486806 (ClinicalTrials.gov) | February 1, 2023 | 2/8/2022 | Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders | Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders | Neurodegenerative Diseases;sca3;MSA - Multiple System Atrophy;Ataxia;Synucleinopathies | Drug: 18F-PBR06;Radiation: 18F-PBR06 | Brigham and Women's Hospital | NULL | Not yet recruiting | 18 Years | N/A | All | 50 | NULL | |
| 7 | EUCTR2022-000336-28-DE (EUCTR) | 12/12/2022 | 28/07/2022 | A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: TAK-341 Product Code: TAK-341 INN or Proposed INN: Not assigned Other descriptive name: Human IgG1 monoclonal antibody against alpha-synuclein | Takeda Development Center Americas, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 138 | Phase 2 | United Kingdom;Italy;Japan;Denmark;Austria;Germany;Portugal;France;United States;Spain | ||
| 8 | NCT05526391 (ClinicalTrials.gov) | November 9, 2022 | 1/9/2022 | A Study of TAK-341 in Treatment of Multiple System Atrophy | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy | Multiple System Atrophy | Drug: TAK-341;Drug: Placebo | Takeda | AstraZeneca | Recruiting | 40 Years | N/A | All | 138 | Phase 2 | United States;Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom |
| 9 | NCT05698017 (ClinicalTrials.gov) | November 7, 2022 | 16/1/2023 | Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA | Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300 | Multiple System Atrophy;MSA - Multiple System Atrophy | Drug: hOMSC300;Other: Sham Procedure | Cytora Ltd. | NULL | Recruiting | 50 Years | 80 Years | All | 18 | Phase 1/Phase 2 | Israel |
| 10 | NCT04165486 (ClinicalTrials.gov) | July 21, 2022 | 14/11/2019 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy | Multiple System Atrophy | Drug: ION464;Drug: Placebo | Ionis Pharmaceuticals, Inc. | NULL | Recruiting | 40 Years | 70 Years | All | 40 | Phase 1 | Austria;France;Germany;United Kingdom;Portugal |
| 11 | NCT05109091 (ClinicalTrials.gov) | July 1, 2022 | 22/10/2021 | Study of ATH434 in Participants With Multiple System Atrophy | A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy | Multiple System Atrophy | Drug: ATH434 dose level 1;Drug: ATH434 dose level 2;Drug: Placebo | Alterity Therapeutics | NULL | Recruiting | 30 Years | 75 Years | All | 60 | Phase 2 | United States;Australia;Italy;New Zealand;United Kingdom |
| 12 | NCT05167721 (ClinicalTrials.gov) | December 15, 2021 | 30/11/2021 | Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | Multiple System Atrophy | Biological: Autologous Mesenchymal Stem Cells;Other: Placebo | Mayo Clinic | NULL | Recruiting | 30 Years | 70 Years | All | 76 | Phase 2 | United States |
| 13 | NCT03446807 (ClinicalTrials.gov) | December 2021 | 20/2/2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not yet recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 14 | NCT05104476 (ClinicalTrials.gov) | November 16, 2021 | 15/10/2021 | A Study of Lu AF82422 in Participants With Multiple System Atrophy | Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy | Multiple System Atrophy | Drug: Lu AF82422;Drug: Placebo | H. Lundbeck A/S | NULL | Active, not recruiting | 40 Years | 75 Years | All | 64 | Phase 2 | United States;Japan |
| 15 | NCT05086094 (ClinicalTrials.gov) | October 14, 2021 | 8/10/2021 | Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA) | Intermediate-Size Patient Population Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA) | Multiple System Atrophy (MSA) | Drug: BHV3241, verdiperstat | Biohaven Pharmaceuticals, Inc. | NULL | No longer available | N/A | N/A | All | United States | ||
| 16 | ChiCTR2100046394 | 2021-06-01 | 2021-05-15 | Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients with Multiple System Atrophy | Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients with Multiple System Atrophy | multiple system atrophy | Experimental group:Drug (tolterodine) combined with electrical stimulation; | Xuanwu Hospital, Capital Medical University | NULL | Recruiting | 30 | 75 | Both | Experimental group:50; | N/A | China |
| 17 | NCT04782830 (ClinicalTrials.gov) | February 5, 2021 | 1/3/2021 | Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms | Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms | Orthostatic; Hypotension, Neurogenic;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy; Hypotension, Parkinsonism | Device: Accelerometer;Drug: placebo pill;Drug: Midodrine or atomoxetine pill | Vanderbilt University Medical Center | NULL | Recruiting | 40 Years | 80 Years | All | 29 | N/A | United States |
| 18 | NCT04620382 (ClinicalTrials.gov) | November 9, 2020 | 27/10/2020 | Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients | Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients | Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease | Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression | Vanderbilt University Medical Center | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 40 Years | 80 Years | All | 31 | Early Phase 1 | United States |
| 19 | NCT04250493 (ClinicalTrials.gov) | October 28, 2020 | 29/1/2020 | Insulin Resistance in Multiple System Atrophy | Insulin Resistance in Multiple System Atrophy | Multiple System Atrophy | Biological: Homeostasis Model Assessment of insulin resistance (HOMA);Behavioral: MOntreal Cognitive Assessment (MoCA);Behavioral: Clinical characteristics of AMS patients;Procedure: Brain Magnetic Resonance Imaging (MRI);Biological: Blood sampling | University Hospital, Bordeaux | University of Bordeaux;Labex Brain;Centre National de la Recherche Scientifique, France | Recruiting | 30 Years | N/A | All | 124 | N/A | France |
| 20 | NCT04876326 (ClinicalTrials.gov) | October 5, 2020 | 25/4/2021 | Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy | Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy | Multiple System Atrophy;Parkinsonism;Multiple System Atrophy, Parkinson Variant | Biological: Autologous Adipose Mesenchymal Stem Cell Implantation;Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation;Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation | Indonesia University | NULL | Recruiting | N/A | N/A | All | 15 | N/A | Indonesia |
| 21 | NCT04431713 (ClinicalTrials.gov) | September 16, 2020 | 29/5/2020 | Exenatide Once-weekly as a Treatment for Multiple System Atrophy | An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy | Multiple System Atrophy | Drug: Exenatide Pen Injector [Bydureon] | University College, London | NULL | Recruiting | 30 Years | 80 Years | All | 50 | Phase 2 | United Kingdom |
| 22 | ChiCTR2000033282 | 2020-06-01 | 2020-05-26 | Construction of cohort and prognosis prediction model of multiple system atrophy | Construction of cohort and prognosis prediction model of multiple system atrophy | Multiple system atrophy | Gold Standard:Clinical outcomes.;Index test:Prognosis prediction model of multiple system atrophy; | West China Hospital of Sichuan University | NULL | Recruiting | 30 | 75 | Both | Target condition:600;Difficult condition:0 | China | |
| 23 | EUCTR2020-000122-26-GB (EUCTR) | 11/05/2020 | 06/04/2020 | Exenatide once-weekly as a treatment for Multiple System Atrophy. | A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy - Exenatide once-weekly as a treatment for Multiple System Atrophy. | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders | Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide | University College London (UCL) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | United Kingdom | ||
| 24 | EUCTR2018-003941-41-AT (EUCTR) | 05/03/2020 | 19/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 258 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 25 | EUCTR2019-001100-38-IT (EUCTR) | 19/02/2020 | 26/01/2021 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) - M-STAR Study | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 Product Code: [/] INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 252 | Phase 3 | France;United States;Austria;Germany;United Kingdom;China;Italy | ||
| 26 | NCT04246437 (ClinicalTrials.gov) | February 4, 2020 | 25/1/2020 | [18F]F-DOPA Imaging in Patients With Autonomic Failure | [18F]F-DOPA Imaging in Patients With Autonomic Failure | Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies | Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose | Daniel Claassen | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 1 | United States |
| 27 | EUCTR2018-003941-41-PT (EUCTR) | 03/02/2020 | 21/08/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 28 | EUCTR2018-003289-15-DE (EUCTR) | 28/01/2020 | 08/02/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Denmark;Bulgaria;Germany | ||
| 29 | EUCTR2018-003289-15-PT (EUCTR) | 13/01/2020 | 21/08/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Denmark;Australia;Peru;Bulgaria;Germany;New Zealand | ||
| 30 | EUCTR2019-001100-38-DE (EUCTR) | 07/01/2020 | 07/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;United Kingdom;Italy;China | ||
| 31 | EUCTR2019-001100-38-AT (EUCTR) | 20/12/2019 | 29/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;United Kingdom;Italy;China | ||
| 32 | EUCTR2019-001100-38-FR (EUCTR) | 13/12/2019 | 03/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 252 | Phase 3 | Austria;United States;Italy;United Kingdom;France;Germany | ||
| 33 | EUCTR2019-001100-38-GB (EUCTR) | 06/12/2019 | 11/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;Italy;United Kingdom | ||
| 34 | NCT03924414 (ClinicalTrials.gov) | November 15, 2019 | 2/4/2019 | Trial of Parkinson's And Zoledronic Acid | TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease | Parkinson Disease;Osteoporosis;Parkinsonism;Parkinson's Disease and Parkinsonism;Atypical Parkinsonism;Progressive Supranuclear Palsy;Multiple System Atrophy;Vascular Parkinsonism;Dementia With Lewy Bodies | Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo | California Pacific Medical Center Research Institute | National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation | Recruiting | 60 Years | N/A | All | 3500 | Phase 4 | United States |
| 35 | NCT03753763 (ClinicalTrials.gov) | October 29, 2019 | 19/11/2018 | Safinamide for Multiple System Atrophy (MSA) | 12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA | Multiple System Atrophy | Drug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placebo | Zambon SpA | NULL | Completed | 30 Years | 80 Years | All | 49 | Phase 2 | Italy;Spain |
| 36 | EUCTR2018-003289-15-BG (EUCTR) | 10/10/2019 | 24/07/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 37 | EUCTR2018-003941-41-BG (EUCTR) | 10/10/2019 | 26/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 258 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 38 | EUCTR2018-003941-41-IT (EUCTR) | 17/09/2019 | 18/01/2021 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: NA Product Code: [TD-9855] INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 258 | Phase 3 | Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand;Estonia;Spain;Ukraine;Portugal;United States | ||
| 39 | NCT04184063 (ClinicalTrials.gov) | September 16, 2019 | 29/7/2019 | Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) | Progressive Supranuclear Palsy;Multiple System Atrophy | Drug: NBMI;Other: Placebo | EmeraMed | NULL | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Slovenia |
| 40 | EUCTR2018-004145-16-IT (EUCTR) | 05/09/2019 | 21/01/2021 | A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy | A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy | Parkinsonian variant of Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xadago Product Name: Xadago Product Code: [Z7219] INN or Proposed INN: SAFINAMIDE METANSOLFONATO Other descriptive name: SAFINAMIDE | ZAMBON SPA | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 2 | Spain;Italy | ||
| 41 | EUCTR2018-003941-41-PL (EUCTR) | 23/08/2019 | 03/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 258 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Denmark;Australia;Peru;Bulgaria;Germany;New Zealand | ||
| 42 | EUCTR2018-003941-41-ES (EUCTR) | 13/08/2019 | 11/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 43 | EUCTR2018-003941-41-GB (EUCTR) | 09/08/2019 | 16/05/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 44 | EUCTR2018-003289-15-IT (EUCTR) | 02/08/2019 | 18/01/2021 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: na Product Code: [TD-9855] INN or Proposed INN: ampreloxetine Other descriptive name: TD-9855 | THERAVANCE BIOPHARMA ANTIBIOTICS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Czechia;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Denmark;Bulgaria;Germany | ||
| 45 | EUCTR2018-003941-41-HU (EUCTR) | 30/07/2019 | 01/08/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 258 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 46 | NCT03952806 (ClinicalTrials.gov) | July 29, 2019 | 15/5/2019 | Study of BHV-3241 in Subjects With Multiple System Atrophy | A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy | Drug: Verdiperstat;Drug: Placebo | Biohaven Pharmaceuticals, Inc. | NULL | Completed | 40 Years | 80 Years | All | 336 | Phase 3 | United States;Austria;France;Germany;Italy;United Kingdom |
| 47 | EUCTR2018-004145-16-ES (EUCTR) | 24/07/2019 | 11/06/2019 | A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy | A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy | Parkinsonian variant of Multiple System Atrophy MedDRA version: 20.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xadago INN or Proposed INN: safinamide methanesulfonate Other descriptive name: SAFINAMIDE | Zambon SpA | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 2 | Spain;Italy | ||
| 48 | EUCTR2018-003289-15-PL (EUCTR) | 19/07/2019 | 07/05/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine chydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 49 | EUCTR2018-003941-41-EE (EUCTR) | 04/07/2019 | 29/05/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood Study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 258 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Denmark;Australia;Peru;Bulgaria;Germany;New Zealand | ||
| 50 | EUCTR2018-003289-15-DK (EUCTR) | 02/07/2019 | 14/03/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Denmark;Australia;Bulgaria;Germany;New Zealand | ||
| 51 | EUCTR2018-003289-15-ES (EUCTR) | 26/06/2019 | 27/06/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Denmark;Germany | ||
| 52 | EUCTR2018-003289-15-HU (EUCTR) | 04/06/2019 | 05/04/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Poland;Denmark;Bulgaria;Germany | ||
| 53 | JPRN-UMIN000036952 | 2019/06/04 | 04/06/2019 | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others. | 18F-FDOPA, 11C-Raclopride PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
| 54 | EUCTR2018-003289-15-AT (EUCTR) | 15/05/2019 | 22/03/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 55 | EUCTR2018-003289-15-GB (EUCTR) | 08/05/2019 | 28/12/2018 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 56 | EUCTR2018-003289-15-EE (EUCTR) | 11/04/2019 | 30/01/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Not Recruiting | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 57 | NCT03901638 (ClinicalTrials.gov) | April 2, 2019 | 24/3/2019 | Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy | Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial | Ataxia, Cerebellar;Multiple System Atrophy | Drug: Tllsh2910;Drug: Placebo | National Taiwan University Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 60 | Phase 3 | Taiwan |
| 58 | EUCTR2018-000506-34-SI (EUCTR) | 04/02/2019 | 09/03/2018 | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: NBMI Product Code: NBMI INN or Proposed INN: emeramide Other descriptive name: N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE | NBMI Science Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Slovenia | ||
| 59 | NCT03589976 (ClinicalTrials.gov) | September 1, 2018 | 5/7/2018 | A Futility Trial of Sirolimus in Multiple System Atrophy | A Single Center Randomized,Double Blind, Placebo-controlled Futility Trial to Determine if Sirolimus is of Sufficient Promise to Slow the Progression of Multiple System Atrophy | Multiple System Atrophy | Drug: Sirolimus 2 MG;Other: Placebo | NYU Langone Health | National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | 30 Years | 80 Years | All | 47 | Phase 2 | United States |
| 60 | NCT03403309 (ClinicalTrials.gov) | May 2, 2018 | 11/1/2018 | Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial | Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial (IMPROVE MSA Study) | Multiple System Atrophy | Drug: 1) Inosine 5'-monophosphate;Drug: Placebo | Yonsei University | NULL | Completed | 19 Years | 75 Years | All | 43 | Phase 2 | Korea, Republic of |
| 61 | NCT03265444 (ClinicalTrials.gov) | April 13, 2018 | 6/8/2017 | Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy | A Phase 1 Study to Evaluate the Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Multiple System Atrophy | Multiple System Atrophy | Biological: CS10BR05 | Corestem, Inc. | NULL | Completed | 30 Years | 75 Years | All | 9 | Phase 1 | Korea, Republic of |
| 62 | NCT03408080 (ClinicalTrials.gov) | December 15, 2017 | 17/1/2018 | Open Pilot Trial of BHV-4157 | An Open Pilot Trial of BHV-4157 in Adult Subjects With Cerebellar Ataxia | Spinocerebellar Ataxias;Spinocerebellar Ataxia Type 1;Spinocerebellar Ataxia Type 2;Spinocerebellar Ataxia 3;Spinocerebellar Ataxia Type 6;MSA-C | Drug: BHV-4157 | University of California, Los Angeles | NULL | Active, not recruiting | 18 Years | 75 Years | All | 24 | Phase 3 | United States |
| 63 | NCT02897063 (ClinicalTrials.gov) | September 2016 | 7/9/2016 | Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure | The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2 | Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension | Drug: Droxidopa;Drug: Midodrine;Drug: Placebo | Vanderbilt University Medical Center | NULL | Recruiting | 40 Years | 80 Years | All | 34 | Phase 1 | United States |
| 64 | NCT02705755 (ClinicalTrials.gov) | May 2016 | 7/3/2016 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension | Drug: TD-9855;Drug: Placebo | Theravance Biopharma | NULL | Completed | 40 Years | N/A | All | 34 | Phase 2 | United States |
| 65 | NCT02796209 (ClinicalTrials.gov) | May 2016 | 7/6/2016 | Norepinephrine Transporter Blockade, Autonomic Failure | Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure | Multiple System Atrophy (MSA) | Drug: Atomexetine;Drug: Placebo | NYU Langone Health | Vanderbilt University Medical Center | Completed | 40 Years | 80 Years | All | 40 | Phase 2 | United States |
| 66 | NCT02994719 (ClinicalTrials.gov) | March 1, 2016 | 21/12/2015 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | NULL | Active, not recruiting | 18 Years | 85 Years | All | 120 | United States | |
| 67 | NCT02591173 (ClinicalTrials.gov) | February 2016 | 27/10/2015 | Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure | Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure | Autonomic Nervous System Disorders;Pure Autonomic Failure;Shy-Drager Syndrome;Orthostatic Hypotension, Dysautonomic | Drug: Angiotensin-(1-7);Drug: Saline | Vanderbilt University Medical Center | NULL | Terminated | 18 Years | 80 Years | All | 7 | Early Phase 1 | United States |
| 68 | NCT02388295 (ClinicalTrials.gov) | April 27, 2015 | 9/3/2015 | AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy | Multiple System Atrophy, MSA | Drug: AZD3241;Drug: Placebo | AstraZeneca | NULL | Completed | 30 Years | 80 Years | All | 59 | Phase 2 | United States;Austria;Finland;France;Italy;Sweden;United Kingdom |
| 69 | EUCTR2014-004902-13-SE (EUCTR) | 14/04/2015 | 02/01/2015 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 100mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Product Name: AZD3241 300mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | France;United States;Finland;Austria;Italy;United Kingdom;Sweden | ||
| 70 | EUCTR2014-004902-13-GB (EUCTR) | 09/04/2015 | 24/12/2014 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 100mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Product Name: AZD3241 300mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 64 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Finland;United Kingdom;Sweden | ||
| 71 | ChiCTR-DPC-15005941 | 2015-03-01 | 2015-01-25 | Study for the diagnosis and differential diagnosis of multiple system atrophy | Study for the diagnosis and differential diagnosis of multiple system atrophy | Multiple system atrophy | Gold Standard:electrophysiological techniques;Index test:brain MRI; | Navy general hospital | NULL | Completed | 30 | 80 | Both | Target condition:260;Difficult condition:0 | China | |
| 72 | EUCTR2014-004902-13-FI (EUCTR) | 11/02/2015 | 31/12/2014 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 100mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Product Name: AZD3241 300mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;France;Finland;Austria;United Kingdom;Italy;Sweden | ||
| 73 | NCT02270489 (ClinicalTrials.gov) | December 11, 2014 | 4/9/2014 | Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA | A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy | Multiple System Atrophy;Neurodegenerative Diseases | Biological: AFFITOPE® PD01A + Adjuvant;Biological: AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active component | Affiris AG | University Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;Forschungszentrum Juelich;University Hospital, Toulouse | Completed | 30 Years | 75 Years | All | 30 | Phase 1 | France |
| 74 | NCT02149901 (ClinicalTrials.gov) | October 2014 | 26/5/2014 | Water and Sudafed in Autonomic Failure | Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure | Shy-Drager Syndrome;Multiple System Atrophy | Drug: Pseudoephedrine + 480 ml water;Drug: Pseudoephedrine + 50 ml water;Other: Placebo + 480 ml water (optional);Other: Placebo + 50 ml water (optional) | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS) | Terminated | 18 Years | 80 Years | All | 35 | Early Phase 1 | United States |
| 75 | EUCTR2012-005539-10-DE (EUCTR) | 29/04/2014 | 18/12/2013 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A | Merz Pharmaceuticals GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | ||
| 76 | NCT02064166 (ClinicalTrials.gov) | February 2014 | 13/2/2014 | Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. | A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy | Parkinson Disease;Multiple System Atrophy | Drug: Intranasal Insulin | Peter Novak | NULL | Completed | 18 Years | N/A | All | 15 | Phase 2 | United States |
| 77 | NCT02071459 (ClinicalTrials.gov) | January 21, 2014 | 21/2/2014 | Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA | Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo | Multiple System Atrophy | Drug: L-Threo DOPS;Drug: placebo | University Hospital, Toulouse | NULL | Completed | 30 Years | 80 Years | All | 107 | Phase 2/Phase 3 | France |
| 78 | NCT02008721 (ClinicalTrials.gov) | January 2014 | 8/12/2013 | Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach | Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA) | Multiple System Atrophy | Drug: EGCG as putative neuroprotective agent;Drug: Placebo | Dr. Johannes Levin | German Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbH | Completed | 18 Years | N/A | Both | 92 | Phase 3 | Germany |
| 79 | EUCTR2012-000928-18-DE (EUCTR) | 21/11/2013 | 28/06/2013 | Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) | Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach | Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sunphenon EGCg INN or Proposed INN: EGCG Other descriptive name: GREEN TEA LEAF | Hospital of the Ludwig-Maximilians-University of Munich | NULL | Not Recruiting | Female: yes Male: yes | 86 | Phase 3 | Germany | ||
| 80 | JPRN-UMIN000011111 | 2013/07/16 | 15/07/2013 | Spinal blood flow and metabolism in neurological diseases | Spinal blood flow and metabolism in neurological diseases - Spinal blood flow and metabolism in neurological diseases | motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy | PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 70 | Not applicable | Japan |
| 81 | JPRN-UMIN000010712 | 2013/05/20 | 15/05/2013 | Ubiquinol for patients with multiple system atrophy | Ubiquinol for patients with multiple system atrophy - Ubiquinol for patients with multiple system atrophy | Patients with multiple system atrophy | Patients with administration of ubiquinol | Department of Neurology, the University of Tokyo Hospital | NULL | Complete: follow-up complete | 30years-old | 80years-old | Male and Female | 1 | Not selected | Japan |
| 82 | JPRN-UMIN000008959 | 2012/11/01 | 16/10/2012 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy - Randomized Double-blind, Placebo-controlled trial on molecular hydrogen water in MSA and PSP | Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan |
| 83 | NCT02315027 (ClinicalTrials.gov) | October 2012 | 31/10/2014 | Mesenchymal Stem Cell Therapy in Multiple System Atrophy | Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History | MSA | Biological: Autologous Mesenchymal Stem Cells | Mayo Clinic | Food and Drug Administration (FDA);National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 30 Years | 80 Years | All | 30 | Phase 1/Phase 2 | United States |
| 84 | NCT01577992 (ClinicalTrials.gov) | December 2011 | 7/11/2011 | Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy | Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy | Pain Threshold;Multiple System Atrophy | Drug: Levodopa test;Procedure: determination of objective and subjective pain threshold | University Hospital, Toulouse | Fondation de France | Completed | 50 Years | 80 Years | Both | 42 | N/A | France |
| 85 | NCT01292694 (ClinicalTrials.gov) | March 2011 | 8/2/2011 | Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure | Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Losartan;Drug: Captopril;Drug: Placebo | Vanderbilt University | NULL | Terminated | 18 Years | 85 Years | All | 12 | Phase 1 | United States |
| 86 | NCT01287221 (ClinicalTrials.gov) | March 2011 | 28/1/2011 | Study of Rifampicin in Multiple System Atrophy | Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy | Multiple System Atrophy | Drug: Rifampicin;Drug: placebo | Phillip Low | National Institute of Neurological Disorders and Stroke (NINDS);Vanderbilt University;Rare Disease Research Network Autonomic Consortium | Terminated | 30 Years | 80 Years | All | 100 | Phase 3 | United States |
| 87 | EUCTR2009-018157-23-GB (EUCTR) | 30/11/2010 | 16/06/2010 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | Multiple system atrophy MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Product Name: AZD3241 Product Code: AZD3241 | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 135 | Phase 2 | United Kingdom;Spain;Austria | ||
| 88 | EUCTR2009-018157-23-AT (EUCTR) | 11/11/2010 | 07/07/2010 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | Multiple system atrophy MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Product Name: AZD3241 Product Code: AZD3241 | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Spain;Austria;United Kingdom | ||
| 89 | EUCTR2009-018157-23-ES (EUCTR) | 14/09/2010 | 23/06/2010 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyEstudio de fase IIa, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de gruposparalelos, de 12 meses de duración para evaluar la eficacia, la seguridad, la tolerabilidad y lafarmacocinética de AZD3241 en pacientes con atrofia multisistémica | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyEstudio de fase IIa, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de gruposparalelos, de 12 meses de duración para evaluar la eficacia, la seguridad, la tolerabilidad y lafarmacocinética de AZD3241 en pacientes con atrofia multisistémica | Multiple system atrophyAtrofia Multisistémica MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Product Name: AZD3241 Product Code: AZD3241 | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 110 | Phase 2 | United Kingdom;Spain;Austria | ||
| 90 | NCT01119417 (ClinicalTrials.gov) | May 2010 | 4/5/2010 | The Role of Endothelin in the Supine Hypertension of Autonomic Failure | The Role of Endothelin in the Supine Hypertension of Autonomic Failure | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: BQ123;Drug: Bq123;Drug: Saline | Vanderbilt University | NULL | Withdrawn | 18 Years | 85 Years | All | 0 | Phase 1 | United States |
| 91 | NCT01136213 (ClinicalTrials.gov) | April 2010 | 26/5/2010 | Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study | Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study | Multiple System Atrophy | Radiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / Placebo | University Hospital, Bordeaux | NULL | Completed | 30 Years | 80 Years | All | 53 | N/A | France |
| 92 | EUCTR2009-014644-11-AT (EUCTR) | 10/03/2010 | 21/10/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 93 | EUCTR2009-014644-11-NL (EUCTR) | 11/02/2010 | 29/10/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 243 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 94 | EUCTR2009-014644-11-PT (EUCTR) | 05/02/2010 | 11/01/2010 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Hungary;Portugal;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 95 | EUCTR2009-014644-11-GB (EUCTR) | 25/01/2010 | 04/08/2010 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;Italy;United Kingdom | ||
| 96 | NCT01044693 (ClinicalTrials.gov) | January 2010 | 6/1/2010 | Nebivolol in the Supine Hypertension of Autonomic Failure | Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mg | Vanderbilt University | Forest Laboratories | Completed | 18 Years | 80 Years | All | 20 | N/A | United States |
| 97 | EUCTR2009-014644-11-IT (EUCTR) | 10/12/2009 | 22/12/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - ND | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - ND | Multiple System Atrophy of the Parkinsonian subtype (MSA-P) MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 98 | EUCTR2009-014644-11-DE (EUCTR) | 08/12/2009 | 15/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | |||
| 99 | NCT00977665 (ClinicalTrials.gov) | December 2009 | 15/9/2009 | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy | Drug: rasagiline mesylate;Drug: placebo | Teva Pharmaceutical Industries | H. Lundbeck A/S | Completed | 30 Years | N/A | All | 174 | Phase 2 | United States;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Spain;United Kingdom |
| 100 | EUCTR2009-014644-11-FR (EUCTR) | 17/11/2009 | 22/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | ||
| 101 | EUCTR2009-016377-15-IT (EUCTR) | 26/10/2009 | 26/10/2009 | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA | Muliple system atrophy MedDRA version: 9.1;Level: HLT;Classification code 10008028 | Trade Name: LITIO CARBONATO INN or Proposed INN: LITHIUM CARBONATE | UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 102 | EUCTR2009-014644-11-ES (EUCTR) | 22/10/2009 | 24/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) | Pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT 1 mg comprimidos INN or Proposed INN: RASAGILINA MESILATO Other descriptive name: RASAGILINA MESILATO | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | ||
| 103 | EUCTR2009-014644-11-HU (EUCTR) | 19/10/2009 | 25/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 104 | NCT00997672 (ClinicalTrials.gov) | October 2009 | 16/10/2009 | Lithium in Multiple System Atrophy | A Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy. | Multiple System Atrophy | Drug: Lithium Carbonate;Drug: Placebo | Federico II University | NULL | Terminated | 18 Years | 80 Years | All | 10 | Phase 2 | Italy |
| 105 | EUCTR2007-004890-24-PT (EUCTR) | 07/10/2008 | 25/06/2008 | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's MedDRA version: 9.1;Classification code 10064060;Term: Multiple system atrophy | Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets Product Code: JP-1730/F01 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets Product Code: JP-1730/F02 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets Product Code: JP-1730/F03 INN or Proposed INN: Fipamezole hydrochloride | Juvantia Pharma Ltd | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Portugal;France | ||
| 106 | NCT00758849 (ClinicalTrials.gov) | September 2008 | 24/9/2008 | Fipamezole in Neurogenic Orthostatic Hypotension | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease | Symptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System Atrophy | Drug: Placebo;Drug: Fipamezole | Juvantia Pharma Ltd | Santhera Pharmaceuticals | Not yet recruiting | 30 Years | 80 Years | Both | 24 | Phase 2 | France;Portugal |
| 107 | NCT00750867 (ClinicalTrials.gov) | June 2008 | 9/9/2008 | Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins | Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins | Multiple System Atrophy | Drug: intravenous immunoglobulin (IVIg) | University of Massachusetts, Worcester | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | United States |
| 108 | NCT00822913 (ClinicalTrials.gov) | June 2008 | 14/1/2009 | Botulinum A Toxin in Patients With Parkinson's Disease | The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. | Parkinson's Disease;Multiple System Atrophy;Detrusor Overactivity | Drug: Intravesical injection of Botulinum A toxin | University Of Perugia | University of Roma La Sapienza | Enrolling by invitation | 18 Years | 80 Years | Both | 20 | Phase 4 | NULL |
| 109 | EUCTR2007-004890-24-FR (EUCTR) | 07/05/2008 | 09/05/2008 | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's MedDRA version: 9.1;Classification code 10064060;Term: Multiple system atrophy | Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets Product Code: JP-1730/F01 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets Product Code: JP-1730/F02 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets Product Code: JP-1730/F03 INN or Proposed INN: Fipamezole hydrochloride | Juvantia Pharma Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 2 | Portugal;France | ||
| 110 | NCT01146548 (ClinicalTrials.gov) | May 2008 | 16/6/2010 | Fluoxetine in Multiple System Atrophy Patients | Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial | Multiple System Atrophy | Drug: FLUOXETINE | University Hospital, Toulouse | Clinical Research Center, Toulouse | Completed | 30 Years | 80 Years | Both | 87 | Phase 2 | France |
| 111 | NCT00911365 (ClinicalTrials.gov) | May 2008 | 26/5/2009 | Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy | A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy | Multiple System Atrophy | Biological: autologous mesenchymal stem cells;Biological: normal saline | Yonsei University | NULL | Completed | N/A | 75 Years | Both | 27 | Phase 2 | Korea, Republic of |
| 112 | EUCTR2007-004922-26-FR (EUCTR) | 12/02/2008 | 31/01/2008 | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | atrophie multisystématisée MedDRA version: 9.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: PROZAC | CHU Toulouse | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 113 | NCT00738062 (ClinicalTrials.gov) | January 2008 | 19/8/2008 | Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase Deficiency | Drug: Droxidopa;Drug: Placebo | Chelsea Therapeutics | NULL | Completed | 18 Years | N/A | All | 103 | Phase 3 | United States;Australia;Canada;New Zealand |
| 114 | NCT00547911 (ClinicalTrials.gov) | October 2007 | 19/10/2007 | Augmenting Effects of L-DOPS With Carbidopa and Entacapone | L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone | Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases | Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Terminated | 18 Years | N/A | All | 14 | Phase 1/Phase 2 | United States |
| 115 | NCT00103597 (ClinicalTrials.gov) | January 2005 | 11/2/2005 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | NULL | Completed | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia |
| 116 | NCT00179023 (ClinicalTrials.gov) | April 2003 | 13/9/2005 | The Autonomic Nervous System and Obesity | The Autonomic Nervous System and Obesity | OBESITY;HYPERTENSION;PURE AUTONOMIC FAILURE;SHY-DRAGER SYNDROME | Drug: Trimethaphan;Drug: Pseudoephedrine | Vanderbilt University | NULL | Completed | 18 Years | 80 Years | All | 128 | Phase 1 | United States |
| 117 | NCT01044992 (ClinicalTrials.gov) | May 2002 | 6/1/2010 | Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study | Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge | Multisystemic Atrophy | Radiation: H215O PET;Drug: Levodopa | University Hospital, Toulouse | NULL | Completed | 40 Years | 75 Years | Both | 38 | N/A | France |
| 118 | NCT00211224 (ClinicalTrials.gov) | April 2000 | 13/9/2005 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) | Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Riluzole | King's College London | Assistance Publique - Hôpitaux de Paris;University of Ulm;Aventis Pharmaceuticals | Terminated | 30 Years | 80 Years | Both | 800 | Phase 3 | United Kingdom |
| 119 | NCT00004478 (ClinicalTrials.gov) | March 1999 | 18/10/1999 | Droxidopa in Treating Patients With Neurogenic Hypotension | Study of Droxidopa in Patients With Neurologic Hypotension | Shy-Drager Syndrome;Orthostatic Hypotension | Drug: droxidopa | Mount Sinai School of Medicine | NULL | Completed | 20 Years | N/A | Both | N/A | United States |